In some patients, rare MET-amplified cells may be found in tissue samples before treatment, suggesting that EGFR-targeted therapies may act as a selective pressure to expand a preexisting subclonal population of cancer cells with MET amplification in a Darwinian fashion [64]. The gene discussed is MET; the disease is cancer.